Indivior develops, manufactures and sells buprenorphine-based prescription drugs for the treatment of opioid dependence worldwide. The Company’s product candidates focus on treating opioid use disorder, alcohol use disorder, overdose rescue and CNS disorders/schizophrenia. It markets and promotes Suboxone sublingual film, Suboxone sublingual tablet and Subutex sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex and Buprenex.

Type
Public
HQ
Slough, GB
Size (employees)
934 (est)
Indivior is headquartered in Slough, GB
Report incorrect company information

Indivior Office Locations

Indivior has offices in Ottawa, Richmond, Slough, Jersey and in 11 other locations
Slough, GB (HQ)
105 Bath Rd
Ottawa, CA
2 Gurdwara Rd
Beijing, CN
1 Dong San Huan Zhong Lu
Massy, FR
15 Rue Ampère
Mannheim, DE
3 Hermsheimer Str.
Milano, IT
7 Via Giovanni Spadolini
Show all (15)
Report incorrect company information

Indivior Financials and Metrics

Indivior Financials

Indivior's revenue was reported to be £823.35 m in FY, 2017
GBP

Revenue (FY, 2017)

823.4 m

Gross profit (FY, 2017)

745 m

Gross profit margin (FY, 2017), %

90.5%

Net income (FY, 2017)

43.7 m

EBITDA (FY, 2017)

150.7 m

EBIT (FY, 2017)

145.4 m

Market capitalization (31-Oct-2017)

2.7 b

Closing share price (31-Oct-2017)

3.5

Cash (31-Dec-2017)

650.1 m

EV

2 b
Indivior's current market capitalization is £2.7 b.
GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

799.6 m762.9 m785.3 m797 m823.4 m

Revenue growth, %

(5%)(9%)18%

Cost of goods sold

68.4 m65 m75.1 m80.6 m78.3 m

Gross profit

731.2 m697.9 m710.2 m716.4 m745 m
GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

4.6 m226.5 m361.7 m521.3 m650.1 m

Accounts Receivable

111.1 m110.8 m130.9 m154.4 m193.6 m

Inventories

23.7 m28.1 m37.2 m30.9 m39.2 m

Current Assets

149.9 m386.6 m558.4 m745.8 m922.8 m
GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

321.6 m275.7 m176.6 m26.4 m43.7 m

Cash From Operating Activities

520.2 m301 m247.8 m306.6 m222.2 m

Dividends Paid

157.2 m17.8 m53.4 m

Cash From Financing Activities

(530 m)(61.6 m)(111.5 m)(110.7 m)(63.3 m)
GBPY, 2017

EV/EBITDA

13.5 x

EV/EBIT

14 x

EV/CFO

9.2 x

Revenue/Employee

906.5 k

Financial Leverage

-7.1 x
Show all financial metrics

Indivior Operating Metrics

Indivior's Clinical Programs was reported to be 12 in FY, 2016.
FY, 2016

Clinical Programs

12

Phase I Trials Products

4

Phase II Trials Products

1

Phase III Trials Products

4
Show all operating metrics
Report incorrect company information

Indivior News and Updates

Dr. Reddy's forced to stop Suboxone generic rollout amid Indivior patent dispute

Dr. Reddy's moved ahead with an "at risk" launch of Indivior's top drug, but now a court has put the rollout on hold until at least June 28.

Indivior Is Granted Temporary Restraining Order

SLOUGH, England, June 15, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that the U.S. District Court for the District of New Jersey has granted Indivior a temporary restraining order (TRO) that compels Dr. Reddy's (DRL) to immediately cease its...

Dr. Reddy's Laboratories announces USFDA final approval and launch of Buprenorphine and Naloxone Sublingual Film in the U.S. Market

HYDERABAD, India and PRINCETON, N.J., June 15, 2018 /PRNewswire/ -- Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has received final approval from the U.S. Food and Drug Administration (USFDA) and is launching Buprenorphine and Naloxone...

Indivior Responds to Generic SUBOXONE® Approvals and Dr. Reddy's Launch "At-Risk"

SLOUGH, England, June 15, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that it is aware that, on 14 June 2018, the US FDA approved generic versions of SUBOXONE® Film from both Dr. Reddy's and Mylan, and that Dr. Reddy's subsequently announced...

Indivior's legal challenges escalate with new Suboxone subpoena from California

Already under fire from U.S. authorities and others, Indivior faces new legal scrutiny from officials in California.

Indivior subpoenaed by California on opioid addiction treatment

May 31 (Reuters) - Britain's Indivior has been subpoenaed by the California Department of Insurance over its blockbuster opioid addiction treatment, Suboxone Film, which is rapidly losing market share due to stiff competition from generic versions.
Show more
Report incorrect company information